Flow outperforms existing treatments1-9

Flow demonstrates effectiveness in both clinical trials and real world data.

Flow has high response and remission rates - with no major side effects1-9.

Odds ratio off white

Clinical trial shows Flow is twice as effective as antidepressants

Flow was tested against a sham headset in a double-blind, randomised controlled trial.

Results show Flow is twice as effective as Antidepressants when compared using an odds ratio: Flow 3.111, Vs Antidepressants 1.682.

Flow has a remission rate of 56% (MADRS scale), or 45% (HDRS-17 Scale)1.

The odds ratio provides information about the relative likelihood of the event occurring in one group (e.g., treatment) compared to the other (e.g., placebo). Flow having an odds ratio twice as large as antidepressant trials means that Flow is twice as likely to be successful in treating depression as antidepressants.

Full results will be published in Autumn 2023.

Graph 1 - rates comparison

Flow outperforms existing treatments in open-label trials1-9

In like-for-like open-label trials, the Flow tDCS Headset reports better remission and response rates compared to standard in-clinic tDCS5-6, antidepressants7-9, and talk therapy9.

The efficacy of tDCS for treating depression has been demonstrated across multiple studies between 2013-20203, 11-12. Together these trials reviewed the outcomes of 7,962 patients using in-clinic tDCS methods. Results across these studies showed tDCS is significantly superior to placebo11, and comparable to TMS12 and SSRI use5.

Graph 2 - remission

Real-world data further support proof of efficacy10

Flow internal data further demonstrates superiority in remission rates compared to other depression treatments10.

In order to access the stimulation headset, users are asked on a weekly basis to complete the Montgomery-Åsberg Depression Rating Scale self-assessment (MADRS-s).

This has enabled Flow to collect a significant amount of real-world data and continue to improve the product and services based on feedback.

Many patient types benefit from Flow10

Flow has been helpful for patients with mild, moderate, and severe depression types.

Flow has over 10,000 headset users and covers patient cases from newly diagnosed to chronic10.


What our users say

“I hope after my lifetime Flow starts to replace meds. It has been rollercoaster of a life depending on horrible drugs with horrible side effects”

Diane Harp

April 12, 2022

"I have been using flow for over 6 months and I’m definitely feeling more positive and this has had an upwards spiraling effect. Starting to eat better, exercise more etc which in turn makes you feel better."

Zoe Abrahams

May 02, 2022

"I’ve moved from a score of about 35 to 12 in the first month on their severity of depression chart. I would say it’s like I no longer feel suicidal or that there is a sense of impending doom"

Joanna Pay

June 22, 2021


1. Double-blinded, placebo-controlled clinical trial (n=173) to measure the effectiveness and safety of Flow’s at-home tDCS depression treatment (2023). Trial took place at University of Texas and the University of East London. PI: Cynthia Fu (Honorary Consultant Psychiatrist at the South London and Maudsley NHS Foundation Trust). Summary of protocol: Link
2. Cipriani, Furukawa, Salanti et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with MDD: meta-analysis. 2018.
3. Fu Cynthia H.Y., et al. J Psychiatr Res. 2022;153:197-205.
4. Borrione L, et al. J Affect Disord. 2021;288:189-190.
5. Brunoni AR, et al. JAMA Psychiatry. 2013;70(4):383-91.
6. Brunoni AR, et al. N Engl J Med. 2017; 376:2523-2533.
7. Machado M, et al. Current medical research and opinion. 2006;22(9),1825–1837.
8. Thase ME, et al. J Clin Psychiatry. 2005;66(8), 974–981.
9. Cuijpers P, et al. Acta Psychiatr Scand. 2021;144:288-299.
10. Data on File.
11. Razza LB, et al. Depress Anxiety. 2020;37:594-608.
12. Mutz J, et al. BMJ. 2019;364:l1079.
13. Trivedi et al. Am J Psychiatry. 2006;163(1):28-40.
14. O.E. Bogucki et al. J Affect Disord. 2021;294:745-752.